GALK2

Across TCGA pan-cancer cohorts, GALK2 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated GALK2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GALK2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GALK2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and UCEC are the cancer types where GALK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	1.000	0.240	.006	14	view →
CCRCC	DFS	Quartile	All	1.000	0.542	.021	13	view →
UCEC	DFS	Quartile	All	1.000	0.877	.018	8	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
HNSC	DFS	Quartile	All	0.333	1.000	.036	6	view →
LUAD	DFS	Median	All	0.893	1.000	.019	4	view →
LSCC	DFS	Median	II,III,IV	0.859	0.970	.034	4	view →
GBM	OS	Median	All	0.289	0.524	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

GALK2–PDAC (OS)

Open the PDAC breakdown →